Cycuria Therapeutics
Pre-clinicalWhile new therapies, such as FLT3 inhibitors and venetoclax-based regimens, have improved initial response rates, durable remissions and long-term survival
Founded
2021
Focus
Biologics
About
While new therapies, such as FLT3 inhibitors and venetoclax-based regimens, have improved initial response rates, durable remissions and long-term survival
Company Info
TypePrivate
Founded2021
LocationVienna, Austria
StagePre-clinical
Contact
SIMILAR COMPANIES
AlgOss Biotechnologies
Pre-clinical · Graz
Angios Biotech
Pre-clinical ·
F4 Pharma
Pre-clinical · Vienna
aTENSION.life
Pre-clinical · Vienna
Austrianni
Pre-clinical · Vienna
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile